 |
![]() |
|
Debajo están las publicaciones claves sobre caspofungina que brindan información de apoyo en un amplio rango de temas. Esta lista no es la bibliografía completa sobre la caspofungina. Publicaciones adicionales sobre caspofungina se pueden encontrar buscando en MEDLINE/PubMed.
|
|
|
| REVISIÓN GENERAL |
|
Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study
Kartsonis N, Saah A, Lipka C, Taylor A y cols. J Infect
2005;50:196–205.
|
|
|
|
|
|
Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study
Kartsonis N, Saah A, Lipka C, Taylor A y cols. J Antimicrob Chemother
2004;53(5):878–881.
|
|
|
|
|
|
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy
Maertens J, Raad I, Petrikkos G y cols. Clin Infect Dis
2004;39:1563–1571.
|
|
|
|
|
|
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia
Walsh TJ, Teppler H, Donowitz GR y cols. N Engl J Med
2004;351(14):1391–1402.
|
|
|
|
|
|
Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin
Dinubile MJ, Lupinacci RJ, Berman RS y cols. AIDS Res Human Retroviruses
2002;18:903–908.
|
|
|
|
|
|
A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis
Villanueva A, Gotuzzo E, Arathoon EG y cols. Am J Med
2002;113:294–299.
|
|
|
|
|
|
Comparison of caspofungin and amphotericin B for invasive candidiasis
Mora-Duarte J, Betts R, Rotstein C y cols. N Engl J Med
2002;347:2020–2029.
|
|
|
|
|
|
In vitro activity of two echinocandin derivatives, LY303366 and MK- 0991 (L-743,792), against clinical isolates of aspergillus, fusarium, rhizopus, and other filamentous fungi.
Pfaller MA, Marco F, Messer SA y cols. Diagn Microbiol Infect Dis
1998;30:251–255.
|
|
|
|
|
|
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).
Bartizal K, Gill CJ, Abruzzo GK y cols. Antimicrob Agents Chemother
1997;41:2326–2332.
|
|
|
|
|
|
In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species.
Vazquez JA, Lynch M, Boikov D y cols. Antimicrob Agents Chemother
1997;41(7):1612–1614.
|
|
|
|
|
|
|
|
|
† Marca registrada de Merck & Co., Inc., Whitehouse Station, NJ, EUA
|
|
|
|
|
